NVIDIA and Eli Lilly showcase distinct growth trajectories, with NVIDIA leading in AI infrastructure scaling and Eli Lilly dominating the GLP-1 market through rapid drug adoption.
NVIDIA is favored as the stronger ten-year compounder due to its AI platform optionality, triple-digit growth, and attractive valuation.
Eli Lilly is recognized as a magnificent defensive-growth pick with strong GLP-1 momentum, but it is not seen as the top ten-year compounder.
NVIDIA and Eli Lilly delivered strong quarterly results, with NVIDIA reporting 106% revenue growth to $96 billion and Eli Lilly growing 48% to $23 billion. While both companies show powerful momentum, NVIDIA stands out as a long-term compounder due to its AI platform optionality and 23x forward earnings valuation, whereas Eli Lilly serves as a defensive-growth play with a lower beta.
NVIDIA offers greater AI platform optionality, triple-digit growth potential, and an attractive valuation relative to its 60% operating margins, whereas Eli Lilly is viewed as a defensive-growth asset.